{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:16:19Z","timestamp":1765610179656,"version":"3.37.3"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Approximately 33% of Crohn\u2019s disease (CD) patients have associated autoimmune skin disease. The pathophysiology of the latter frequently involves interleukin-12\/interleukin-23 signaling pathways that may also impact gut inflammation. Ustekinumab is an anti-IL-12\/23 FDA-approved biologic for psoriasis and inflammatory bowel disease. However, its relative efficacy has never been studied in CD with autoimmune skin disease (CD-ASD) vs CD without autoimmune skin disease (CD-none).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is a retrospective, single-center, case-control study comparing markers of disease activity between CD-ASD and CD-none. Biomarkers (fecal calprotectin [FCP], C-reactive protein [CRP]) prior to drug initiation and after at least 5 months of standard IBD dose ustekinumab therapy were extracted from the medical record. In addition, 2 blinded observers performed 5-point Likert scoring before and after endoscopic, pathologic, and imaging reports.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In all, 395 CD patients received ustekinumab therapy (79 CD-ASD, 316 CD-none). Patients were similar in age; gender; ethnicity; CD severity, phenotype, and duration; tobacco, immunomodulator, and steroid use. Ustekinumab had greater efficacy in CD-ASD when evaluated by FCP (P = .0337) and CRP (P = .078). The CD-ASD group also showed better outcomes in Likert scores of endoscopy (P = .016), histopathology (P = .074), and imaging (P = .094). In all Likert parameters, CD-ASD had more patients with complete resolution of moderate\/severe disease (P &amp;lt; .05). Additional subanalyses for surgeries, ulcers, abscesses, fistulas, and colitis were conducted, with colitis reaching statistical significance (P = .0011).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Concurrent autoimmune skin disease in CD is associated with greater ustekinumab effectiveness in controlling intestinal inflammation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izab201","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T20:38:17Z","timestamp":1633034297000},"page":"895-904","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of Ustekinumab in Crohn\u2019s Disease With and Without Concurrent Autoimmune Skin Disease"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5987-5827","authenticated-orcid":false,"given":"Elena","family":"Fradkov","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Michigan , Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Sheehan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Michigan , Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3914-9673","authenticated-orcid":false,"given":"Kelly","family":"Cushing","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Michigan , Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter D R","family":"Higgins","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Michigan , Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"2022092301480165800_CIT0001","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am J Gastroenterol."},{"key":"2022092301480165800_CIT0002","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fphys.2012.00013","article-title":"Skin manifestations of inflammatory bowel disease","volume":"3","author":"Huang","year":"2012","journal-title":"Front Physiol."},{"key":"2022092301480165800_CIT0003","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/01.MIB.0000436959.62286.f9","article-title":"Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy","volume":"20","author":"Marzano","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"2022092301480165800_CIT0004","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.det.2015.03.007","article-title":"Cutaneous manifestations of crohn disease","volume":"33","author":"Hagen","year":"2015","journal-title":"Dermatol Clin."},{"key":"2022092301480165800_CIT0005","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/07853890903559724","article-title":"Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management","volume":"42","author":"Larsen","year":"2010","journal-title":"Ann Med."},{"key":"2022092301480165800_CIT0006","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10020364","article-title":"Dermatological manifestations in inflammatory bowel diseases","volume":"10","author":"Antonelli","year":"2021","journal-title":"J Clin Med"},{"key":"2022092301480165800_CIT0007","doi-asserted-by":"crossref","first-page":"8192150","DOI":"10.1155\/2017\/8192150","article-title":"Metastatic crohn\u2019s disease: an approach to an uncommon but important cutaneous disorder","volume":"2017","author":"Aberumand","year":"2017","journal-title":"Biomed Res Int."},{"key":"2022092301480165800_CIT0008","first-page":"225","article-title":"Dermatologic manifestations of inflammatory bowel disease: a review","volume":"25","author":"Keyal","year":"2018","journal-title":"Discov Med."},{"key":"2022092301480165800_CIT0009","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/pde.13565","article-title":"Cutaneous manifestations of metastatic Crohn\u2019s disease","volume":"35","author":"Schneider","year":"2018","journal-title":"Pediatr Dermatol."},{"key":"2022092301480165800_CIT0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3748\/wjg.v24.i1.15","article-title":"Updated review on immune factors in pathogenesis of Crohn\u2019s disease","volume":"24","author":"Li","year":"2018","journal-title":"World J Gastroenterol."},{"key":"2022092301480165800_CIT0011","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00296-005-0044-9","article-title":"The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease","volume":"26","author":"Turkcapar","year":"2006","journal-title":"Rheumatol Int."},{"key":"2022092301480165800_CIT0012","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/jid.2011.466","article-title":"Identification of quantitative trait loci in experimental epidermolysis bullosa acquisita","volume":"132","author":"Ludwig","year":"2012","journal-title":"J Invest Dermatol."},{"key":"2022092301480165800_CIT0013","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.imlet.2018.01.014","article-title":"The role of gut microbiota and IL-23\/IL-17 pathway in ankylosing spondylitis immunopathogenesis: New insights and updates","volume":"196","author":"Babaie","year":"2018","journal-title":"Immunol Lett."},{"key":"2022092301480165800_CIT0014","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/08916934.2011.606446","article-title":"The role of natural killer cells in autoimmune blistering diseases","volume":"45","author":"Zakka","year":"2012","journal-title":"Autoimmunity."},{"key":"2022092301480165800_CIT0015","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/cmi.2012.15","article-title":"New insights of T cells in the pathogenesis of psoriasis","volume":"9","author":"Cai","year":"2012","journal-title":"Cell Mol Immunol."},{"key":"2022092301480165800_CIT0016","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jaci.2015.06.032","article-title":"Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing","volume":"136","author":"Su\u00e1rez-Fari\u00f1as","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"2022092301480165800_CIT0017","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2500\/aap.2015.36.3808","article-title":"Serum interleukin 17, interleukin 23, and interleukin 10 values in children with atopic eczema\/dermatitis syndrome (AEDS): association with clinical severity and phenotype","volume":"36","author":"Leonardi","year":"2015","journal-title":"Allergy Asthma Proc."},{"key":"2022092301480165800_CIT0018","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3389\/fimmu.2018.01323","article-title":"The interleukin-23\/interleukin-17 axis links adaptive and innate immunity in psoriasis","volume":"9","author":"Sch\u00f6n","year":"2018","journal-title":"Front Immunol."},{"key":"2022092301480165800_CIT0019","first-page":"281","article-title":"Cutaneous side effects of TNF-alpha inhibitors","volume":"15","author":"Lindhaus","year":"2017","journal-title":"J Dtsch Dermatol Ges."},{"key":"2022092301480165800_CIT0020","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40257-017-0296-7","article-title":"Clinical signs, pathophysiology and management of cutaneous side effects of anti-tumor necrosis factor agents","volume":"18","author":"Segaert","year":"2017","journal-title":"Am J Clin Dermatol."},{"article-title":"Ustekinumab as induction and maintenance therapy for crohn\u2019s disease","author":"Feagan","key":"2022092301480165800_CIT0021","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1602773"},{"key":"2022092301480165800_CIT0022","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.5070\/D32210032898","article-title":"Ustekinumab for treatment of cutaneous Crohn\u2019s disease","volume":"22","author":"Abdat","year":"2016","journal-title":"Dermatol Online J"},{"key":"2022092301480165800_CIT0023","first-page":"69","article-title":"Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn\u2019s disease","volume":"12","author":"Matsumoto","year":"2018","journal-title":"Biologics."},{"key":"2022092301480165800_CIT0024","doi-asserted-by":"crossref","first-page":"328","DOI":"10.36849\/JDD.2020.2106","article-title":"Tumor necrosis factor inhibitor-induced psoriasis in a pediatric crohn\u2019s disease patient successfully treated with ustekinumab","volume":"19","author":"Bonomo","year":"2020","journal-title":"J Drugs Dermatol."},{"key":"2022092301480165800_CIT0025","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/1346-8138.14816","article-title":"Ustekinumab for skin reactions associated with anti-tumor necrosis factor-\u03b1 agents in patients with inflammatory bowel diseases: a single-center retrospective study","volume":"46","author":"Ezzedine","year":"2019","journal-title":"J Dermatol."},{"key":"2022092301480165800_CIT0026","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ecco-jcc\/jjx178","article-title":"Cutaneous morbidity among inflammatory bowel disease patients: a cohort study","volume":"12","author":"Vide","year":"2018","journal-title":"J Crohns Colitis."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/28\/6\/895\/45977542\/izab201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/28\/6\/895\/45977542\/izab201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T01:49:20Z","timestamp":1663897760000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/28\/6\/895\/6378368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,9,30]]},"published-print":{"date-parts":[[2022,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izab201","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"type":"print","value":"1078-0998"},{"type":"electronic","value":"1536-4844"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2021,9,30]]}}}